Agilent Technologies (NYSE:A) Stock Rating Reaffirmed by 58.com

Agilent Technologies (NYSE:A – Get Rating)‘s stock had its “maintains” rating reissued by stock analysts at 58.com in a note issued to investors on Wednesday, Benzinga reports.

A number of other research analysts have also commented on A. Evercore ISI lowered their price objective on shares of Agilent Technologies from $150.00 to $126.00 and set an “outperform” rating on the stock in a research note on Wednesday. Credit Suisse Group cut their target price on shares of Agilent Technologies from $170.00 to $160.00 and set an “outperform” rating for the company in a research report on Wednesday. Wells Fargo & Company cut their target price on shares of Agilent Technologies from $170.00 to $160.00 and set an “overweight” rating for the company in a research report on Wednesday. Stifel Nicolaus cut their price target on shares of Agilent Technologies from $153.00 to $135.00 and set a “hold” rating on the stock in a report on Wednesday. Finally, Barclays dropped their target price on shares of Agilent Technologies from $140.00 to $135.00 and set an “equal weight” rating on the stock in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $151.35.

Agilent Technologies Price Performance

A stock opened at $119.49 on Wednesday. The stock’s 50 day moving average price is $133.52 and its 200 day moving average price is $143.94. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.53 and a current ratio of 2.11. The firm has a market cap of $35.33 billion, a P/E ratio of 26.32, a PEG ratio of 1.89 and a beta of 1.03. Agilent Technologies has a 1 year low of $112.52 and a 1 year high of $160.26.

Agilent Technologies (NYSE:A – Get Rating) last released its quarterly earnings data on Tuesday, May 23rd. The medical research company reported $1.27 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.01. Agilent Technologies had a return on equity of 30.74% and a net margin of 19.19%. The business had revenue of $1.72 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same period in the prior year, the firm posted $1.13 EPS. The business’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, sell-side analysts expect that Agilent Technologies will post 5.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of A. Synovus Financial Corp boosted its stake in shares of Agilent Technologies by 2.3% in the first quarter. Synovus Financial Corp now owns 6,751 shares of the medical research company’s stock worth $895,000 after acquiring an additional 153 shares during the last quarter. Blair William & Co. IL grew its stake in shares of Agilent Technologies by 7.3% in the first quarter. Blair William & Co. IL now owns 28,606 shares of the medical research company’s stock valued at $3,785,000 after buying an additional 1,957 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in Agilent Technologies by 52.1% during the 1st quarter. Sequoia Financial Advisors LLC now owns 2,334 shares of the medical research company’s stock worth $309,000 after purchasing an additional 799 shares in the last quarter. Vanguard Group Inc. grew its stake in Agilent Technologies by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 24,531,170 shares of the medical research company’s stock worth $3,246,209,000 after purchasing an additional 261,435 shares in the last quarter. Finally, Zions Bancorporation N.A. grew its stake in Agilent Technologies by 10.8% during the 1st quarter. Zions Bancorporation N.A. now owns 2,880 shares of the medical research company’s stock worth $381,000 after purchasing an additional 281 shares in the last quarter. 85.51% of the stock is currently owned by hedge funds and other institutional investors.

Agilent Technologies Company Profile

(Get Rating)

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.